poisar

Stocks · News reference

uniQure Announces Additional Data From Ongoing Phase I/II Studies Of Ifezuntirgene Inilparvovec For Treatment Of Huntington’s Disease; In 12 High-Dose Patients At 48 Months, Both cUHDRS And TFC Continued To Demonstrate Meaningful Slowing Of Disease Progression And Clear Dose-Dependent Response; Primary Endpoint Of cUHDRS Showed 44% Slowing Of Disease Progression

Benzinga Newsdesk

~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

QURE
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Kirby Mcinerney Llp

    UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

    Law firm Kirby McInerney LLP is investigating potential securities law violations by uniQure N.V. following the release of 48-month data for AMT-130 that showed significantly reduced treatment efficacy (44% disease slowing) compared to previously reported 36-month results (75% slowing). The company had submitted an FDA application based on the stronger 36-month data. uniQure's stock price declined 37.3% on the news, falling from $39.11 to $24.51 per share.

    QURE